At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as oncology, inflammation and metabolic disorders.

23 June 2009: MDRNA, Inc. Regains Full Compliance With All Marketplace Rules to Remain on the NASDAQ Global Market

19 June 2009: MDRNA, Inc. Gains Full Financial and Transactional Control of Its Proprietary UNA Technology